Načítá se...
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
Chronic myeloid leukemia was the first haematological neoplasia that benefited from a targeted therapy with imatinib nearly 15 years ago. Since then, several studies have investigated the role of genes, their variants (i.e., polymorphisms) and their encoded proteins in the pharmacokinetics and pharm...
Uloženo v:
| Vydáno v: | Int J Mol Sci |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4613337/ https://ncbi.nlm.nih.gov/pubmed/26402671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms160922811 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|